Director/PDMR Shareholding

RNS Number : 4156J

Destiny Pharma PLC

26 April 2022

 

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Notification of Transactions by Persons Discharging Managerial Responsibilities (PDMRs)/Persons Closely Associated (PCAs)

Brighton, United Kingdom - 26 April 2022 - Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that it was notified on 26 April 2022 that on that same day, Dr William Love, Chief Scientific Officer of the Company, transferred 580,000 ordinary shares of 1 pence in the Company ("Ordinary Shares") to his wife, a PCA, by way of gift for nil consideration.

Following the transfer, Dr William Love's beneficial interest in the Company remains unchanged at 6,509,500 Ordinary Shares, representing 8.88 per cent. of the total issued share capital.

For further information, please contact: 

Destiny Pharma plc 

Neil Clark, CEO 

Shaun Claydon, CFO 

[phone] 

[e-mail]

Optimum Strategic Communications 

Mary Clark / Manel Mateus / Vici Rabbetts

[phone]

[e-mail]

finnCap Ltd  (Nominated Advisor and Broker)

Geoff Nash / Kate Bannatyne / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

[phone]

MC Services AG

Anne Hennecke / Andreas Burckhardt

[phone]

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information, please visit  www.destinypharma.com  

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Dr William Love
2.	Reason for the Notification
a)	Position/status	Chief Scientific Officer
b)	Initial notification/Amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 1p each ("Ordinary Shares")
	Identification code	DEST  GB00BDHSP575
b)	Nature of the transaction	Transfer of Ordinary Shares, by way of gift, to Carol Love, a Person Closely Associated with him, for nil consideration.
c)	Price(s) and volume(s)	Price(s) Volume(s) 0 (gift) 580,000
d)	Aggregated information: · Aggregated volume · Price	See 4c) above
e)	Date of the transaction	26 April 2022
f)	Place of the transaction	Off-Market

 

END

 

 

DSHFLFFSSFIRFIF